165 related articles for article (PubMed ID: 25003617)
21. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
22. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
23. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
24. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Maekawa S; Iwasaki A; Shirakusa T; Enatsu S; Kawakami T; Kuroki M; Kuroki M
Anticancer Res; 2007; 27(6A):3735-41. PubMed ID: 17970036
[TBL] [Abstract][Full Text] [Related]
25. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
26. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
27. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
28. Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model.
Yashiro M; Shinto O; Nakamura K; Tendo M; Matsuoka T; Matsuzaki T; Kaizaki R; Ohira M; Miwa A; Hirakawa K
Br J Cancer; 2009 Oct; 101(7):1100-6. PubMed ID: 19738610
[TBL] [Abstract][Full Text] [Related]
29. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
Achen MG; Williams RA; Baldwin ME; Lai P; Roufail S; Alitalo K; Stacker SA
Growth Factors; 2002 Jun; 20(2):99-107. PubMed ID: 12148568
[TBL] [Abstract][Full Text] [Related]
30. [Expression of vascular endothelial growth factor (VEGF) C and VEGF receptor 3 in non-small cell lung cancer].
Dong X; Qiu XS; Wang EH; Li QC; Gu W
Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):128-32. PubMed ID: 12839674
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
32. [Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer].
Chen YN; Gu Y
Ai Zheng; 2009 Dec; 28(12):1337-43. PubMed ID: 19958632
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S; Wissmann C; Jöns T; Vieth M; Hertel J; Gretschel S; Schlag PM; Kemmner W; Höcker M
J Clin Oncol; 2006 Jan; 24(2):228-40. PubMed ID: 16344322
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
Kim JY; Bae BN; Kwon JE; Kim HJ; Park K
APMIS; 2011 Jul; 119(7):449-59. PubMed ID: 21635552
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis.
Coso S; Zeng Y; Opeskin K; Williams ED
PLoS One; 2012; 7(6):e39558. PubMed ID: 22745786
[TBL] [Abstract][Full Text] [Related]
36. Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia.
Nihei M; Okazaki T; Ebihara S; Kobayashi M; Niu K; Gui P; Tamai T; Nukiwa T; Yamaya M; Kikuchi T; Nagatomi R; Ebihara T; Ichinose M
J Pathol; 2015 Mar; 235(4):632-45. PubMed ID: 25348279
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of lymphangiogenesis of endothelial progenitor cells with VEGFR-3 siRNA delivered with PEI-alginate nanoparticles.
Li T; Wang GD; Tan YZ; Wang HJ
Int J Biol Sci; 2014; 10(2):160-70. PubMed ID: 24520214
[TBL] [Abstract][Full Text] [Related]
38. New model of in-situ xenograft lymphangiogenesis by a human colonic adenocarcinoma cell line in nude mice.
Sun JJ; Jing W; Ni YY; Yuan XJ; Zhou HH; Fan YZ
Asian Pac J Cancer Prev; 2012; 13(6):2823-8. PubMed ID: 22938466
[TBL] [Abstract][Full Text] [Related]
39. Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway.
Yu J; Zhang X; Kuzontkoski PM; Jiang S; Zhu W; Li DY; Groopman JE
Cell Commun Signal; 2014 Apr; 12():25. PubMed ID: 24708522
[TBL] [Abstract][Full Text] [Related]
40. Soluble Vegfr3 gene therapy suppresses multi-organ metastasis in a mouse mammary cancer model.
Shibata MA; Shibata E; Tanaka Y; Shiraoka C; Kondo Y
Cancer Sci; 2020 Aug; 111(8):2837-2849. PubMed ID: 32539229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
